| Trial ID # | NCT02606305; FORWARD II |
| Phase | Ib/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Pembrolizumab, Mirvetuximab soravtansine |
| Eligible Participant | Platinum resistant FRalpha+ ovarian cancer; IHC: ≥ 25% tumor cells at ≥ 2+ intensity |
| Patients Enrolled | 56; median 3 prior therapies (2-7) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, RP2D, evaluated per RECIST |
| Biomarkers | FRalpha protein |
| Efficacy | RP2D: Pem 200mg + Mir 6mg/kg q3w Exploratory analysis; medium/high FRalpha: ≥ 50% of tumor cells with ≥ 2+ FRalpha expression: |
| Clinically Significant Adverse Events | Serious AE: one treatment-related death (encephalitis) |
| Conclusion | Encouraging activity in FRalpha+ patients |
| Reference | Matulonis UA et al. Initial safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (Frα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in platinum-resistant epithelial ovarian cancer patients. SGO (2018) Abstract 74 Matulonis UA et al. Mirvetuximab soravtansine, a folate receptor alpha (Frα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovariancancer (PROC): Initial results of an expansion cohort from FORWARD II, a Phase Ib study. Ann Oncol (2018) 29 Suppl_8, Abstract 949P, Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.